Lys Therapeutics
Created in 2021
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
2,715Activities
Technologies
Entity types
Location
56 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 12
SIREN
895069904Engaged corporates
13
4 8Added in Motherbase
1 year, 1 month ago
biotech Value proposition
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a biotechnology company pioneering a breakthrough approach to treat patients suffering from neurodegenerative or neurovascular disorders. Its main drug is a first-in-class monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action.
It is demonstrated that one endogenous protease called tissue plasminogen activator (tPA) is implicated in the pathophysiology of neurological diseases such as multiple sclerosis, Parkinson’s disease, stroke and other neurodegenerative disorders through its overexpression and binding to NMDA receptors (NMDAr) present on vascular endothelial cells and regulating the blood brain barrier (BBB) function / dysfunction. The overactivation of vascular NMDAr is triggering a strong increase of the permeability of the BBB allowing the transmigration of toxic immune cells to the brain parenchyma leading to neuroinflammation, ultimately causing neurodegeneration.
By blocking the tPA-NMDAr interaction inside the blood vessels, Glunozumab is restoring both NMDAr and blood-brain barrier physiological functioning (no perturbation of basal function), blocking both neuroinflammatory and neurodegenerative processes.
This unique mechanism of action implies that Glunozumab does not need to cross the BBB to act on the central nervous system, which is a distinctive feature for the treatment of neurological diseases.
Targeting major societal impact, the clinical development of Glunozumab biotherapy is of priority for Lys Therapeutics, as a potential game changer for patients suffering from neurological disorders with high unmet medical needs.
More information on lystherapeutics.com
Stroke, Multiple Sclerosis, Neurology, Neurodegenerative disorders, Healthcare, Biotechnology, Pharma, Drug development, Antibody, Parkinson, Parkinson's Disease, and Neurovascular diseasesOriginal language
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a biotechnology company pioneering a breakthrough approach to treat patients suffering from neurodegenerative or neurovascular disorders. Its main drug is a first-in-class monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action.
It is demonstrated that one endogenous protease called tissue plasminogen activator (tPA) is implicated in the pathophysiology of neurological diseases such as multiple sclerosis, Parkinson’s disease, stroke and other neurodegenerative disorders through its overexpression and binding to NMDA receptors (NMDAr) present on vascular endothelial cells and regulating the blood brain barrier (BBB) function / dysfunction. The overactivation of vascular NMDAr is triggering a strong increase of the permeability of the BBB allowing the transmigration of toxic immune cells to the brain parenchyma leading to neuroinflammation, ultimately causing neurodegeneration.
By blocking the tPA-NMDAr interaction inside the blood vessels, Glunozumab is restoring both NMDAr and blood-brain barrier physiological functioning (no perturbation of basal function), blocking both neuroinflammatory and neurodegenerative processes.
This unique mechanism of action implies that Glunozumab does not need to cross the BBB to act on the central nervous system, which is a distinctive feature for the treatment of neurological diseases.
Targeting major societal impact, the clinical development of Glunozumab biotherapy is of priority for Lys Therapeutics, as a potential game changer for patients suffering from neurological disorders with high unmet medical needs.
More information on lystherapeutics.com
Home - Lys Therapeutics
Lys Therapeutics, first-in-class biotherapies against neurological diseases
https://lystherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Biogen Biotechnology, Biotechnology Research | Biogen Biotechnology, Biotechnology Research | Other 22 Mar 2024 | | |
 La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | Other 13 Mar 2024 | | |
 PULSALYS Research, Research Services | PULSALYS Research, Research Services | Other 6 Feb 2024 | | |
 MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 22 Jan 2024 | | |
 Ouest-France Media, Newspaper Publishing | Ouest-France Media, Newspaper Publishing | Other 20 Nov 2023 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 10 Oct 2023 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 10 Oct 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 20 Nov 2023 | | |
 Pôle TES Public business cluster, French Cluster, Business Consulting and Services | Pôle TES Public business cluster, French Cluster, Business Consulting and Services | Other 24 Sep 2023 | | |
 Société des Neurosciences NGO, Think Tank, Civic and Social Organizations | Société des Neurosciences NGO, Think Tank, Civic and Social Organizations | Other 26 May 2023 | | |